Abstract:Background and ObjectivesA quantitative evaluation of the PK of meropenem, a broad-spectrum β-lactam antibiotic, in plasma and interstitial space fluid (ISF) of subcutaneous adipose tissue of obese patients is lacking as of date. The objective of this study was the characterisation of meropenem population pharmacokinetics in plasma and ISF in obese and non-obese patients for identification of adequate dosing regimens via Monte-Carlo simulations.MethodsWe obtained plasma and microdialysate concentrations after administration of meropenem 1000 mg to 15 obese and 15 non-obese surgery patients from a prospective clinical trial. After characterizing plasma- and microdialysis-derived ISF pharmacokinetics via population pharmacokinetic analysis, we simulated thrice-daily (TID) meropenem short-term (0.5 h), prolonged (3.0 h), and continuous infusions. Adequacy of therapy was assessed by the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment (PTA) analysis based on time unbound concentrations exceeded minimum inhibitory concentrations (MIC) on treatment day 1 (%fT > MIC) and the sum of PTA weighted by relative frequency of MIC values for infections by pathogens commonly treated with meropenem. To avoid interstitial tissue fluid concentrations below MIC for the entire dosing interval during continuous infusions, a more conservative PK/PD index was selected (%fT > 4 × MIC).ResultsAdjusted body weight (ABW) and calculated creatinine clearance (CLCRCG_ABW) of all patients (body mass index [BMI] = 20.5–81.5 kg/m2) explained a considerable proportion of the between-patient pharmacokinetic variability (15.1–31.0% relative reduction). The ISF:plasma ratio of %fT > MIC was relatively similar for MIC ≤ 2 mg/L but decreased for MIC = 8 mg/L over ABW = 60–120 kg (0.50–0.20). Steady-state concentrations were 2.68 times (95% confidence interval [CI] = 2.11–3.37) higher in plasma than in ISF, supporting PK/PD targets related to four times the MIC during continuous infusions to avoid suspected ISF concentrations constantly below the MIC. A 3000 mg/24 h continuous infusion was sufficient at MIC = 2 mg/L for patients with CLCRCG_ABW ≤ 100 mL/min and ABW < 90 kg, whereas 2000 mg TID prolonged infusions were adequate for those with CLCRCG_ABW ≤ 100 mL/min and ABW > 90 kg. For MIC = 2 mg/L and %fT> MIC = 95, PTA was adequate in patients over the entire investigated range of body mass and renal function using a 6000 mg continuous infusion. A prolonged infusion of meropenem 2000 mg TID was sufficient for MIC ≤ 8 mg/L and all investigated ABW and CLCRCG_ABW when employing the PK/PD target %fT > MIC = 40. Short-term infusions of 1000 mg TID were sufficient for CLCRCG_ABW ≤ 130 mL/min and distributions of MIC values for Escherichia coli, Citrobacter freundii, and Klebsiella pneumoniae but not for Pseudomonas aeruginosa.ConclusionsThis analysis indicated a need for higher doses (≥ 2000 mg) and prolonged infusions (≥ 3 h) for obese and non-obese patients at MIC ≥ 2 mg/L. Higher PTA was achieved with prolonged infusions in obese patients and with continuous infusions in non-obese patients.Trial RegistrationEudraCT: 2012-004383-22.

Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia

Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection

Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem in CKD and Hemodialysis Individuals

Pharmacokinetic/Pharmacodynamic Analysis Of Imipenem In Plasma And Peritoneal Liquid In Chinese Patients With Perforated Upper Gastrointestinal Tract

Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients

Effects of Uric Acid, Creatinine Clearance, and Infusion Duration on the Population Pharmacokinetics of Meropenem in Critically Ill Patients

Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation

Changes of PK/PD of Meropenem in patients with abdominal septic shock and exploration of clinical rational administration plan: a prospective exploratory study

Precision Dosing of Meropenem in Adults with Normal Renal Function: Insights from a Population Pharmacokinetic and Monte Carlo Simulation Study

Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis

Predictors for non-attainment of meropenem target concentrations when treating infections in critically ill patients

611. Meropenem Dosage Optimization in Critically Ill Patients Based on a Population Pharmacokinetic Approach.

Optimal Dose of Meropenem for the Treatment of Neonatal Sepsis: Dosing Guideline Variations and Clinical Practice Deviations

Optimal Dosing Regimen of Biapenem in Chinese Patients with Lower Respiratory Tract Infections Based on Population Pharmacokinetic/pharmacodynamic Modelling and Monte Carlo Simulation

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis

Population Pharmacokinetics, Dosing Optimization and Clinical Outcomes of Biapenem in Patients with Sepsis

Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients-a prospective cohort study

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous Versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients